Literature DB >> 8515298

Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992.

H C Neu1, A P Wilson, R N Grüneberg.   

Abstract

A review of the published literature detailing the clinical use of amoxycillin/clavulanic acid spanning the period 1979 to 1992 was undertaken to assess the clinical efficacy of the product and to determine whether any changes had occurred during this time. In the 415 publications meeting the selection criteria a total of over 38,500 patients were treated with amoxycillin/clavulanic acid. Analysis of the data confirms the efficacy of amoxycillin/clavulanic acid over a wide range of clinical indications and annual and triennial groupings of publications suggests that there has been little change in the clinical effectiveness of amoxycillin/clavulanic acid. Clinical efficacy rates (cure or improved) with amoxycillin/clavulanic acid were 88% and 92% in comparative and uncontrolled trials, respectively. Gastro-intestinal side effects are the most common adverse event but have been relatively infrequent. Amoxycillin/clavulanic acid should continue to be a useful antibiotic for upper and lower respiratory tract infections, skin structure infections, dental, head and neck infections, and selected urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8515298     DOI: 10.1080/1120009x.1993.11739213

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  7 in total

Review 1.  Cancer: science and society and the communication of risk.

Authors:  K C Calman
Journal:  BMJ       Date:  1996-09-28

2.  Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis.

Authors:  P Krijnen; C J Kaandorp; E W Steyerberg; D van Schaardenburg; H J Moens; J D Habbema
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 3.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

4.  Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments.

Authors:  Anne-Claude Crémieux; Claudette Muller-Serieys; Xavière Panhard; Frédérique Delatour; Marina Tchimichkian; France Mentre; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin.

Authors:  A S Beale; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection.

Authors:  P J Cook; J M Andrews; J Woodcock; R Wise; D Honeybourne
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

7.  Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice.

Authors:  N C Karalus; J E Garrett; S D Lang; R A Leng; G N Kostalas; R T Cursons; B C Cooper; C J Ryan
Journal:  Infection       Date:  1995       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.